Prescribing information

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Discover a variety of on-demand webinars providing information on multiple sclerosis and KESIMPTA.

If you would like to express interest in future events, please use the ‘Contact’ button, and a Novartis representative will be in contact.

Video preview ‘Developing a Kesimpta (ofatumumab) patient pathway for your MS service protocol’. Video discusses ‘the treating of MS patients outside of the hospital setting’.

Developing a KESIMPTA patient pathway for your MS service protocol

Watch Dr David Paling and Ms Joela Mathews discuss the treating of MS patients outside of the hospital setting.

Watch

Recording. Image preview of a micraphone. With text underneath ‘Kesimpta Launch meeting’. Recording discusses ‘key themes and topics on RRMS and Kesimpta’

KESIMPTA Launch event

Watch and hear MS experts answer questions, and discuss key themes and topics on RRMS and KESIMPTA.

Access

 

Image preview of a play button. With text underneath ‘Kesimpta Regional launch meeting’.

KESIMPTA Regional launch meetings

Watch MS experts in your area introduce KESIMPTA’s mode of action, dosing and administration, and clinical efficacy and safety.

Watch

 

MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.

Rate this content: 
Average: 5 (1 vote)
UK | November 2021 | 167367
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]